Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-center Study to Evaluate the Safety and Efficacy of ABI-007 Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Phase 2, Multi-center Study to Evaluate the Safety and Efficacy of ABI-007 Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Adenocarcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PANC-001
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 03 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 10 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 08 Jun 2015 Planned End Date changed from 1 Dec 2016 to 1 Oct 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top